WAEPS 2023 Annual Meeting Physician Program

Question Title

* 1. Please rate the following Thursday (03/9/23) sessions from 1 – 5 (1 =
unsatisfactory; 5 = exemplary).

	1 - unsatisfactory	2 -	3 - Neutral	4 -	5 - Exemplary
Therapeutic Restoration of Dynamic Range of Focus Utilizing Laser Scleral Microporation \| Mitchell Jackson, MD \| 7:00-7:35 p.m.	Therapeutic Restoration of Dynamic Range of Focus Utilizing Laser Scleral Microporation \| Mitchell Jackson, MD \| 7:00-7:35 p.m. 1 - unsatisfactory	Therapeutic Restoration of Dynamic Range of Focus Utilizing Laser Scleral Microporation \| Mitchell Jackson, MD \| 7:00-7:35 p.m. 2 -	Therapeutic Restoration of Dynamic Range of Focus Utilizing Laser Scleral Microporation \| Mitchell Jackson, MD \| 7:00-7:35 p.m. 3 - Neutral	Therapeutic Restoration of Dynamic Range of Focus Utilizing Laser Scleral Microporation \| Mitchell Jackson, MD \| 7:00-7:35 p.m. 4 -	Therapeutic Restoration of Dynamic Range of Focus Utilizing Laser Scleral Microporation \| Mitchell Jackson, MD \| 7:00-7:35 p.m. 5 - Exemplary
Malpractice Prevention Presentation \| Dan Briceland, MD of OMIC and Aaron Weingeist, MD of OMIC \| 7:35-8:30 p.m.	Malpractice Prevention Presentation \| Dan Briceland, MD of OMIC and Aaron Weingeist, MD of OMIC \| 7:35-8:30 p.m. 1 - unsatisfactory	Malpractice Prevention Presentation \| Dan Briceland, MD of OMIC and Aaron Weingeist, MD of OMIC \| 7:35-8:30 p.m. 2 -	Malpractice Prevention Presentation \| Dan Briceland, MD of OMIC and Aaron Weingeist, MD of OMIC \| 7:35-8:30 p.m. 3 - Neutral	Malpractice Prevention Presentation \| Dan Briceland, MD of OMIC and Aaron Weingeist, MD of OMIC \| 7:35-8:30 p.m. 4 -	Malpractice Prevention Presentation \| Dan Briceland, MD of OMIC and Aaron Weingeist, MD of OMIC \| 7:35-8:30 p.m. 5 - Exemplary
Pilots and Physicians, Passengers and Patients – Maintaining Awareness When Stakes are High \| Tamara Fountain, MD \| 8:30-9:05 p.m.	Pilots and Physicians, Passengers and Patients – Maintaining Awareness When Stakes are High \| Tamara Fountain, MD \| 8:30-9:05 p.m. 1 - unsatisfactory	Pilots and Physicians, Passengers and Patients – Maintaining Awareness When Stakes are High \| Tamara Fountain, MD \| 8:30-9:05 p.m. 2 -	Pilots and Physicians, Passengers and Patients – Maintaining Awareness When Stakes are High \| Tamara Fountain, MD \| 8:30-9:05 p.m. 3 - Neutral	Pilots and Physicians, Passengers and Patients – Maintaining Awareness When Stakes are High \| Tamara Fountain, MD \| 8:30-9:05 p.m. 4 -	Pilots and Physicians, Passengers and Patients – Maintaining Awareness When Stakes are High \| Tamara Fountain, MD \| 8:30-9:05 p.m. 5 - Exemplary

Question Title

* 2. Please rate the following Friday (03/10/23) sessions from 1 – 5 (1 =
unsatisfactory; 5 = exemplary).

	1 - Unsatisfactory	2 -	3 - Neutral	4 -	5 - Exemplary
The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 1 \| Daniel Martin, MD \| 8:00-8:20 a.m.	The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 1 \| Daniel Martin, MD \| 8:00-8:20 a.m. 1 - Unsatisfactory	The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 1 \| Daniel Martin, MD \| 8:00-8:20 a.m. 2 -	The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 1 \| Daniel Martin, MD \| 8:00-8:20 a.m. 3 - Neutral	The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 1 \| Daniel Martin, MD \| 8:00-8:20 a.m. 4 -	The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 1 \| Daniel Martin, MD \| 8:00-8:20 a.m. 5 - Exemplary
The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 2 \| Daniel Martin, MD \| 8:20-8:45 a.m.	The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 2 \| Daniel Martin, MD \| 8:20-8:45 a.m. 1 - Unsatisfactory	The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 2 \| Daniel Martin, MD \| 8:20-8:45 a.m. 2 -	The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 2 \| Daniel Martin, MD \| 8:20-8:45 a.m. 3 - Neutral	The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 2 \| Daniel Martin, MD \| 8:20-8:45 a.m. 4 -	The DRCR Retina Network: Clinical Trials we Did and Didn’t Do and Why Part 2 \| Daniel Martin, MD \| 8:20-8:45 a.m. 5 - Exemplary
How Low Can You Go? Ptosis From Kids to Adult \| Tamara Fountain, MD \| 8:50-9:10 a.m.	How Low Can You Go? Ptosis From Kids to Adult \| Tamara Fountain, MD \| 8:50-9:10 a.m. 1 - Unsatisfactory	How Low Can You Go? Ptosis From Kids to Adult \| Tamara Fountain, MD \| 8:50-9:10 a.m. 2 -	How Low Can You Go? Ptosis From Kids to Adult \| Tamara Fountain, MD \| 8:50-9:10 a.m. 3 - Neutral	How Low Can You Go? Ptosis From Kids to Adult \| Tamara Fountain, MD \| 8:50-9:10 a.m. 4 -	How Low Can You Go? Ptosis From Kids to Adult \| Tamara Fountain, MD \| 8:50-9:10 a.m. 5 - Exemplary
Quantitative Postoperative Satisfaction in Patients with Premium IOLS \| Mitchell Jackson, MD \| 9:10-9:35 a.m.	Quantitative Postoperative Satisfaction in Patients with Premium IOLS \| Mitchell Jackson, MD \| 9:10-9:35 a.m. 1 - Unsatisfactory	Quantitative Postoperative Satisfaction in Patients with Premium IOLS \| Mitchell Jackson, MD \| 9:10-9:35 a.m. 2 -	Quantitative Postoperative Satisfaction in Patients with Premium IOLS \| Mitchell Jackson, MD \| 9:10-9:35 a.m. 3 - Neutral	Quantitative Postoperative Satisfaction in Patients with Premium IOLS \| Mitchell Jackson, MD \| 9:10-9:35 a.m. 4 -	Quantitative Postoperative Satisfaction in Patients with Premium IOLS \| Mitchell Jackson, MD \| 9:10-9:35 a.m. 5 - Exemplary
Rubbing You the Wrong Way—Making Entropion Disappear \| Tamara Fountain, MD \| 10:15-10:35 a.m.	Rubbing You the Wrong Way—Making Entropion Disappear \| Tamara Fountain, MD \| 10:15-10:35 a.m. 1 - Unsatisfactory	Rubbing You the Wrong Way—Making Entropion Disappear \| Tamara Fountain, MD \| 10:15-10:35 a.m. 2 -	Rubbing You the Wrong Way—Making Entropion Disappear \| Tamara Fountain, MD \| 10:15-10:35 a.m. 3 - Neutral	Rubbing You the Wrong Way—Making Entropion Disappear \| Tamara Fountain, MD \| 10:15-10:35 a.m. 4 -	Rubbing You the Wrong Way—Making Entropion Disappear \| Tamara Fountain, MD \| 10:15-10:35 a.m. 5 - Exemplary
s Trabeculectomy a Dead Procedure? \| Richard Schroeder, MD \| 10:35-10:55 a.m.	s Trabeculectomy a Dead Procedure? \| Richard Schroeder, MD \| 10:35-10:55 a.m. 1 - Unsatisfactory	s Trabeculectomy a Dead Procedure? \| Richard Schroeder, MD \| 10:35-10:55 a.m. 2 -	s Trabeculectomy a Dead Procedure? \| Richard Schroeder, MD \| 10:35-10:55 a.m. 3 - Neutral	s Trabeculectomy a Dead Procedure? \| Richard Schroeder, MD \| 10:35-10:55 a.m. 4 -	s Trabeculectomy a Dead Procedure? \| Richard Schroeder, MD \| 10:35-10:55 a.m. 5 - Exemplary
Protecting the Cornea: Genetics to the Rescue or Not? \| Mitchell Jackson, MD \| 10:55-11:15 a.m.	Protecting the Cornea: Genetics to the Rescue or Not? \| Mitchell Jackson, MD \| 10:55-11:15 a.m. 1 - Unsatisfactory	Protecting the Cornea: Genetics to the Rescue or Not? \| Mitchell Jackson, MD \| 10:55-11:15 a.m. 2 -	Protecting the Cornea: Genetics to the Rescue or Not? \| Mitchell Jackson, MD \| 10:55-11:15 a.m. 3 - Neutral	Protecting the Cornea: Genetics to the Rescue or Not? \| Mitchell Jackson, MD \| 10:55-11:15 a.m. 4 -	Protecting the Cornea: Genetics to the Rescue or Not? \| Mitchell Jackson, MD \| 10:55-11:15 a.m. 5 - Exemplary
Modern Day Management of Angle Closure Glaucoma \| Richard Schroeder, MD \| 11:15-11:40 a.m.	Modern Day Management of Angle Closure Glaucoma \| Richard Schroeder, MD \| 11:15-11:40 a.m. 1 - Unsatisfactory	Modern Day Management of Angle Closure Glaucoma \| Richard Schroeder, MD \| 11:15-11:40 a.m. 2 -	Modern Day Management of Angle Closure Glaucoma \| Richard Schroeder, MD \| 11:15-11:40 a.m. 3 - Neutral	Modern Day Management of Angle Closure Glaucoma \| Richard Schroeder, MD \| 11:15-11:40 a.m. 4 -	Modern Day Management of Angle Closure Glaucoma \| Richard Schroeder, MD \| 11:15-11:40 a.m. 5 - Exemplary
Comparison of Routine VA Measurements in Retinal Clinical Practice vs ETDRS Protocol VA \| Daniel Martin, MD \| 2:00-2:20 p.m.	Comparison of Routine VA Measurements in Retinal Clinical Practice vs ETDRS Protocol VA \| Daniel Martin, MD \| 2:00-2:20 p.m. 1 - Unsatisfactory	Comparison of Routine VA Measurements in Retinal Clinical Practice vs ETDRS Protocol VA \| Daniel Martin, MD \| 2:00-2:20 p.m. 2 -	Comparison of Routine VA Measurements in Retinal Clinical Practice vs ETDRS Protocol VA \| Daniel Martin, MD \| 2:00-2:20 p.m. 3 - Neutral	Comparison of Routine VA Measurements in Retinal Clinical Practice vs ETDRS Protocol VA \| Daniel Martin, MD \| 2:00-2:20 p.m. 4 -	Comparison of Routine VA Measurements in Retinal Clinical Practice vs ETDRS Protocol VA \| Daniel Martin, MD \| 2:00-2:20 p.m. 5 - Exemplary
Man’s Best Friend (Until It’s Not) –Dog Bites and Eyeballs \| Tamara Fountain, MD \| 2:20-2:40 p.m.	Man’s Best Friend (Until It’s Not) –Dog Bites and Eyeballs \| Tamara Fountain, MD \| 2:20-2:40 p.m. 1 - Unsatisfactory	Man’s Best Friend (Until It’s Not) –Dog Bites and Eyeballs \| Tamara Fountain, MD \| 2:20-2:40 p.m. 2 -	Man’s Best Friend (Until It’s Not) –Dog Bites and Eyeballs \| Tamara Fountain, MD \| 2:20-2:40 p.m. 3 - Neutral	Man’s Best Friend (Until It’s Not) –Dog Bites and Eyeballs \| Tamara Fountain, MD \| 2:20-2:40 p.m. 4 -	Man’s Best Friend (Until It’s Not) –Dog Bites and Eyeballs \| Tamara Fountain, MD \| 2:20-2:40 p.m. 5 - Exemplary
How Should We Choose the Right MIGS Procedure? \| Richard Schroeder, MD \| 2:40-3:00 p.m.	How Should We Choose the Right MIGS Procedure? \| Richard Schroeder, MD \| 2:40-3:00 p.m. 1 - Unsatisfactory	How Should We Choose the Right MIGS Procedure? \| Richard Schroeder, MD \| 2:40-3:00 p.m. 2 -	How Should We Choose the Right MIGS Procedure? \| Richard Schroeder, MD \| 2:40-3:00 p.m. 3 - Neutral	How Should We Choose the Right MIGS Procedure? \| Richard Schroeder, MD \| 2:40-3:00 p.m. 4 -	How Should We Choose the Right MIGS Procedure? \| Richard Schroeder, MD \| 2:40-3:00 p.m. 5 - Exemplary
Marking Astigmatism Prior to Cataract Surgery \| Mitchell Jackson, MD \| 3:00-3:20 p.m.	Marking Astigmatism Prior to Cataract Surgery \| Mitchell Jackson, MD \| 3:00-3:20 p.m. 1 - Unsatisfactory	Marking Astigmatism Prior to Cataract Surgery \| Mitchell Jackson, MD \| 3:00-3:20 p.m. 2 -	Marking Astigmatism Prior to Cataract Surgery \| Mitchell Jackson, MD \| 3:00-3:20 p.m. 3 - Neutral	Marking Astigmatism Prior to Cataract Surgery \| Mitchell Jackson, MD \| 3:00-3:20 p.m. 4 -	Marking Astigmatism Prior to Cataract Surgery \| Mitchell Jackson, MD \| 3:00-3:20 p.m. 5 - Exemplary
Scientific Presentation #15 \| Mitchell Jackson, MD \| 3:55-4:15 p.m.	Scientific Presentation #15 \| Mitchell Jackson, MD \| 3:55-4:15 p.m. 1 - Unsatisfactory	Scientific Presentation #15 \| Mitchell Jackson, MD \| 3:55-4:15 p.m. 2 -	Scientific Presentation #15 \| Mitchell Jackson, MD \| 3:55-4:15 p.m. 3 - Neutral	Scientific Presentation #15 \| Mitchell Jackson, MD \| 3:55-4:15 p.m. 4 -	Scientific Presentation #15 \| Mitchell Jackson, MD \| 3:55-4:15 p.m. 5 - Exemplary
Important Clinical Questions: Current and Planned Trials in the DRCR Retinal Network \| Daniel Martin, MD \| 4:15-4:35 p.m.	Important Clinical Questions: Current and Planned Trials in the DRCR Retinal Network \| Daniel Martin, MD \| 4:15-4:35 p.m. 1 - Unsatisfactory	Important Clinical Questions: Current and Planned Trials in the DRCR Retinal Network \| Daniel Martin, MD \| 4:15-4:35 p.m. 2 -	Important Clinical Questions: Current and Planned Trials in the DRCR Retinal Network \| Daniel Martin, MD \| 4:15-4:35 p.m. 3 - Neutral	Important Clinical Questions: Current and Planned Trials in the DRCR Retinal Network \| Daniel Martin, MD \| 4:15-4:35 p.m. 4 -	Important Clinical Questions: Current and Planned Trials in the DRCR Retinal Network \| Daniel Martin, MD \| 4:15-4:35 p.m. 5 - Exemplary
Sticks & Stones and Broken Bones: Managing Orbit Trauma \| Tamara Fountain, MD \| 4:35-4:55 p.m.	Sticks & Stones and Broken Bones: Managing Orbit Trauma \| Tamara Fountain, MD \| 4:35-4:55 p.m. 1 - Unsatisfactory	Sticks & Stones and Broken Bones: Managing Orbit Trauma \| Tamara Fountain, MD \| 4:35-4:55 p.m. 2 -	Sticks & Stones and Broken Bones: Managing Orbit Trauma \| Tamara Fountain, MD \| 4:35-4:55 p.m. 3 - Neutral	Sticks & Stones and Broken Bones: Managing Orbit Trauma \| Tamara Fountain, MD \| 4:35-4:55 p.m. 4 -	Sticks & Stones and Broken Bones: Managing Orbit Trauma \| Tamara Fountain, MD \| 4:35-4:55 p.m. 5 - Exemplary
Falling Flat – Management of Complications in Glaucoma Surgery \| Richard Schroeder, MD \| 4:55-5:15 p.m.	Falling Flat – Management of Complications in Glaucoma Surgery \| Richard Schroeder, MD \| 4:55-5:15 p.m. 1 - Unsatisfactory	Falling Flat – Management of Complications in Glaucoma Surgery \| Richard Schroeder, MD \| 4:55-5:15 p.m. 2 -	Falling Flat – Management of Complications in Glaucoma Surgery \| Richard Schroeder, MD \| 4:55-5:15 p.m. 3 - Neutral	Falling Flat – Management of Complications in Glaucoma Surgery \| Richard Schroeder, MD \| 4:55-5:15 p.m. 4 -	Falling Flat – Management of Complications in Glaucoma Surgery \| Richard Schroeder, MD \| 4:55-5:15 p.m. 5 - Exemplary

Question Title

* 3. Having attended the program, rate your ability to:

	No Change	Some Increase	Significant Increase
Use OCT parameter to support the diagnosis of glaucoma.	Use OCT parameter to support the diagnosis of glaucoma. No Change	Use OCT parameter to support the diagnosis of glaucoma. Some Increase	Use OCT parameter to support the diagnosis of glaucoma. Significant Increase
Identify red flags on the pre op evaluation for cataract surgery.	Identify red flags on the pre op evaluation for cataract surgery. No Change	Identify red flags on the pre op evaluation for cataract surgery. Some Increase	Identify red flags on the pre op evaluation for cataract surgery. Significant Increase
Improve outcomes in refractive outcomes in cataract surgery.	Improve outcomes in refractive outcomes in cataract surgery. No Change	Improve outcomes in refractive outcomes in cataract surgery. Some Increase	Improve outcomes in refractive outcomes in cataract surgery. Significant Increase
Manage pre and post op inflammation in uveitis patients.	Manage pre and post op inflammation in uveitis patients. No Change	Manage pre and post op inflammation in uveitis patients. Some Increase	Manage pre and post op inflammation in uveitis patients. Significant Increase
Determine steps in management of patients when initial assessments prove incorrect	Determine steps in management of patients when initial assessments prove incorrect No Change	Determine steps in management of patients when initial assessments prove incorrect Some Increase	Determine steps in management of patients when initial assessments prove incorrect Significant Increase
Identify common artifacts that cause false positive and false negative results in visual fields.	Identify common artifacts that cause false positive and false negative results in visual fields. No Change	Identify common artifacts that cause false positive and false negative results in visual fields. Some Increase	Identify common artifacts that cause false positive and false negative results in visual fields. Significant Increase
Decide which glaucoma surgical patients benefit from a tube vs a trab as primary glaucoma surgery.	Decide which glaucoma surgical patients benefit from a tube vs a trab as primary glaucoma surgery. No Change	Decide which glaucoma surgical patients benefit from a tube vs a trab as primary glaucoma surgery. Some Increase	Decide which glaucoma surgical patients benefit from a tube vs a trab as primary glaucoma surgery. Significant Increase
Be aware of the differential diagnosis of acquired esotropia in children.	Be aware of the differential diagnosis of acquired esotropia in children. No Change	Be aware of the differential diagnosis of acquired esotropia in children. Some Increase	Be aware of the differential diagnosis of acquired esotropia in children. Significant Increase

Question Title

* 4. A "commercial interest" is defined as any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. Among the exemptions to this definition are government organizations, non-health care related companies and non-profit organizations that do not advocate for commercial interests. Did you perceive any bias toward a "commercial interest" in any presentation?

Yes

No

Question Title

* 5. What patient problems or challenges would you like to see WAEPS address in future CME programs?

Question Title

* 6. Please name at least one change to your practice you will implement as a result of this meeting.

Question Title

* 7. What are the barriers to implementing the competencies learned into your practice?

Question Title

* 8. Next year, what would you like to hear more of?

Question Title

* 9. Next year, what would you like to hear less of?

Question Title

* 10. Any other comments and suggestions to help plan for next year:

Question Title

* 11. I attended this course for ___ total hours of CME credit.

Question Title

* 12. Please enter your name for CME accreditation purposes.

Question Title

* 13. Are you a Washington State Medical Association (WSMA) member?

Yes

No